{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:50:09Z","timestamp":1788922209730,"version":"build-2803163510"},"reference-count":57,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100014232","name":"Helsedirektoratet","doi-asserted-by":"publisher","award":["Evaluation of HAT clinics research grant; 20\/00546"],"award-info":[{"award-number":["Evaluation of HAT clinics research grant; 20\/00546"]}],"id":[{"id":"10.13039\/501100014232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Heroin-assisted treatment (HAT) is an evidence-based treatment option for opioid use disorder (OUD), available in a limited number of countries. Norway implemented a 5-year HAT project in 2022, aiming to assess its effectiveness and its potential integration into the country\u2019s OUD treatment system. This study describes and compares patients\u2019 baseline characteristics from the Oslo and Bergen HAT clinics, providing a comprehensive picture of the unique population and the real-world application of HAT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This cross-sectional study examines the baseline characteristics of consenting HAT patients within the first 2\u2009years of operation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200986). Self-reported questionnaires gathered sociodemographics, previous treatment experiences, self-reported crime, and substance use, as well as motivations and expectations for treatment. Comparisons between the clinics were carried out using\n                      <jats:italic>t<\/jats:italic>\n                      -tests, Mann\u2013Whitney\n                      <jats:italic>U<\/jats:italic>\n                      tests, Chi-square, and Fisher\u2019s exact test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The majority of the patients were enrolled at the Oslo clinic (76%) and were male (80%). At admission, the average age was 45.9, with a significantly younger group in Bergen (42.5 vs 47.3,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.05). While no patients reported being unhoused, 17% noted unstable housing within the preceding month. Unemployment was prevalent (91%) alongside previous treatment experiences (95%), with a median of 2 prior medication types. In the 3\u2009months preceding HAT initiation, 78% of patients reported being victims of crime, and 44% committed at least one crime. Over their lifetime, 2 in 5 participants (41%) had experienced an unwanted overdose and 43% had shared syringes and equipment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study reveals a cohort experiencing societal marginalization, including unstable housing, unsatisfactory prior OUD treatment, high-risk behaviors, and frequent interactions with criminal activities, predominantly as victims. While the Oslo and Bergen clinics serve a similar patient profile, notable differences emerged in the reasons for discontinuing past OUD treatment and crime-related factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342241271991","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:13:49Z","timestamp":1743743629000},"page":"13-24","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient Characteristics From Norway\u2019s First Heroin-Assisted Treatment Clinics"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-4491","authenticated-orcid":false,"given":"Francesca","family":"Melis","sequence":"first","affiliation":[{"name":"Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2421-4201","authenticated-orcid":false,"given":"Thomas","family":"Clausen","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4069-1040","authenticated-orcid":false,"given":"Charlotte","family":"Castel","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-2170","authenticated-orcid":false,"given":"Omid","family":"Dadras","sequence":"additional","affiliation":[{"name":"Bergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3320-3800","authenticated-orcid":false,"given":"Silvana","family":"De Pirro","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Bergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5152-0141","authenticated-orcid":false,"given":"Lars Henrik","family":"Myklebust","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9523-8698","authenticated-orcid":false,"given":"Ann","family":"Oldervoll","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Elise","family":"W\u00fcsthoff","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Unit for Clinical Research on Addictions, Department of Research and Innovation, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-9099","authenticated-orcid":false,"given":"Desiree","family":"Eide","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/adm.0000000000000606"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03140.x"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3126"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0137-5"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.06.020"},{"issue":"3","key":"e_1_3_3_9_2","first-page":"200","article-title":"Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone?","volume":"63","author":"Srivastava A","year":"2017","unstructured":"Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician. 2017;63(3):200-205.","journal-title":"Can Fam Physician"},{"issue":"2","key":"e_1_3_3_10_2","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick RP","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Db Syst Rev. 2014;2014(2):CD002207.","journal-title":"Cochrane Db Syst Rev"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.7249\/WR1263"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.149195"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15601"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0962-y"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00808-8"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109869"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2009.00100.x"},{"key":"e_1_3_3_19_2","unstructured":"Demaret I Litran G Magoga C et al. Projet TADAM: RAPPORT FINAL 2007-2013. 2013. Accessed February 12 2024. https:\/\/www.relia-lhw.be\/RELIASNEWS\/RELIAENL25\/doc%20nl25\/tadam.rapportfinal.pdf"},{"key":"e_1_3_3_20_2","unstructured":"Jugend-an Drogenh\u00ebllef. Rapport annuel 2022 [Annual report 2022]. 2022. Accessed February 12 2024. https:\/\/jdh.lu\/wp-content\/uploads\/2024\/01\/Rapport-annuel-2022-JDH.pdf"},{"key":"e_1_3_3_21_2","unstructured":"University of Oslo. HAB \u2013 evaluation of heroin-assisted treatment. Universitet i Oslo. Updated April 15 2021. Accessed February 12 2024. https:\/\/www.med.uio.no\/klinmed\/english\/research\/projects\/hab-evaluation-heroin-assisted-treatment\/index.html"},{"key":"e_1_3_3_22_2","unstructured":"Glasgow City Council. Scotland\u2019s first heroin assisted treatment unveiled. 2023. Accessed February 12 2024. https:\/\/www.glasgow.gov.uk\/article\/25326\/Scotlands-First-Heroin-Assisted-Treatment-Unveiled"},{"key":"e_1_3_3_23_2","unstructured":"Scottish Government. National mission on drugs annual report 2022-2023. 2023. Accessed February 12 2024. https:\/\/www.gov.scot\/binaries\/content\/documents\/govscot\/publications\/progress-report\/2023\/10\/national-mission-drugs-annual-report-2022-23\/documents\/national-mission-drugs-annual-report-2022-2023\/national-mission-drugs-annual-report-2022-2023\/govscot%3Adocument\/national-mission-drugs-annual-report-2022-2023.pdf"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/14550725231207251"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-10767-w"},{"key":"e_1_3_3_26_2","unstructured":"EMCDDA EMCfDaDA. Statistical Bulletin 2023 \u2014 problem drug use. https:\/\/www.emcdda.europa.eu\/data\/stats2023\/pdu_en#displayTable:PDU-1-2"},{"key":"e_1_3_3_27_2","unstructured":"Nesse L Lobmaier P Skeie I Lillevold PH Clausen T. Statusrapport 2023. Tjuefem \u00e5r med legemiddelassisert rehabilitering (LAR) [Status report 2022. First year with new OAT guidelines]. 2024. Accessed February 20 2024. https:\/\/www.med.uio.no\/klinmed\/forskning\/sentre\/seraf\/publikasjoner\/rapporter\/2024\/seraf-rapport-nr-2-2024-statusrapport-2023.pdf"},{"key":"e_1_3_3_28_2","unstructured":"EMCDDA EMCfDaDA. Viral hepatitis elimination barometer among people who inject drugs in Europe. 2024. Updated November 2023. Accessed June 24 2024. https:\/\/www.emcdda.europa.eu\/publications\/data-factsheet\/viral-hepatitis-elimination-barometer-among-people-who-inject-drugs-in-europe_en#section0"},{"key":"e_1_3_3_29_2","unstructured":"Norwegian Directorate of Health. Nasjonale anbefalinger r\u00e5d pakkeforl\u00f8p og pasientforl\u00f8p [National recommendations advice package progress and patient progress.]. Online document. Norwegian Directorate of Health. 2024. Updated January 24 2017. Accessed June 24 2024. https:\/\/www.helsedirektoratet.no\/retningslinjer\/behandling-og-rehabilitering-av-rusmiddelproblemer-og-pendendingen"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/1455072518815322"},{"key":"e_1_3_3_31_2","unstructured":"Nesse L Lobmaier P Skeie I Lillevold PH Clausen T. Statusrapport 2022. F\u00f8rste \u00e5r med nye LAR-retningslinjer [Status report 2022. First year with new LAR guidelines]. 2023. https:\/\/www.med.uio.no\/klinmed\/forskning\/sentre\/seraf\/publikasjoner\/rapporter\/2023\/seraf-rapport-nr-1-2023-statusrapport-2022.pdf"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2014.05.007"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-4382-9"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01764-9"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109281"},{"key":"e_1_3_3_36_2","unstructured":"Norwegian Institute of Public Health. Drug-induced deaths 2023. 2024. Updated May 30 2024. Accessed June 19 2024. https:\/\/www.fhi.no\/le\/rusmidler-og-avhengighet\/narkotikainorge\/konsekvenser-av-narkotikabruk\/narkotikautloste-dodsfall\/?term=#referanser"},{"key":"e_1_3_3_37_2","unstructured":"Statistics Norway. Population and land area in urban settlements. Updated December 12 2023. Accessed February 12 2024. https:\/\/www.ssb.no\/en\/befolkning\/folketall\/statistikk\/tettsteders-befolkning-og-areal"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02406-5"},{"key":"e_1_3_3_39_2","unstructured":"Norwegian Directorate of Health. Buprenorfin og metadon anbefales som substitusjonslegemiddel i LAR. Ved utilstrekkelig behandlingseffekt eller vesentlige bivirkninger av buprenorfin og metadon b\u00f8r levometadon eller langtidsvirkende morfin vurderes [Buprenorphine and methadone are recommended as substitution medication in Opioid Maintenance Treatment (OMT). In case of insufficient treatment effect or significant side effects of buprenorphine and methadone levomethadone or long-acting morphine should be considered]. Norwegian Directorate of Health. Updated November 30 2022. Accessed February 12 2024. https:\/\/www.helsedirektoratet.no\/retningslinjer\/behandling-ved-opioidavhengighet\/behandling-ved-opioidavhengighet\/buprenorfin-og-metadon-anbefales-som-substitusjonslegemiddel-i-lar.ved-utilstrekkelig-behandlingseffekt-eller-vesentlige-bivirkninger-av-buprenorfin-og-metadon-bor-levometadon-eller-langtidsvirkende-morfin-vurderes#referere"},{"key":"e_1_3_3_40_2","unstructured":"Norwegian Directorate of Health. No f\u00e5r LAR-pasientar morfin som varer i 24 timar [Now OMT patients get morphine that lasts for 24 hours]. Norwegian Directorate of Health. Updated September 4 2023. Accessed February 12 2024. https:\/\/www.helsedirektoratet.no\/nyheter\/no-far-lar-pasientar-morfin-som-varer-i-24-timar"},{"key":"e_1_3_3_41_2","unstructured":"Oslo University Hospital. Retningslinje. HABiO. Obligatorisk bruk av opioidscore f\u00f8r og etter inntak av diacetylmorfin (DAM) [Mandatory use of opioid score before and after intake of diacetylmorphine (DAM).]. 2024. Accessed February 15 2024. https:\/\/ehandboken.ous-hf.no\/document\/143458"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-008-9312-9"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111051"},{"key":"e_1_3_3_44_2","unstructured":"Statistics Norway. Educational attainment of the population. Updated July 5 2023. Accessed February 12 2024. https:\/\/www.ssb.no\/en\/utdanning\/utdanningsniva\/statistikk\/befolkningens-utdanningsniva"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0439-1"},{"key":"e_1_3_3_46_2","unstructured":"Norwegian Ministry of Local Government and Modernisation. We all need a safe place to call home. National strategy for social housing policies (2021-2024). 2020. Accessed February 15 2024. https:\/\/www.regjeringen.no\/en\/dokumenter\/we-all-need-a-safe-place-to-call-home-national-strategy-for-sosial-housing-policies-2021-2024\/id2788470\/"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.18261\/issn.2464-4161-2021-01-05"},{"key":"e_1_3_3_48_2","unstructured":"Danish Health Authority. Evaluering af ordningen med l\u00e6geordineret heroin til opioidafh\u00e6ngige patienter. Opg\u00f8relse over \u00e5rene 2013-2020 [Evaluation of the scheme with medical-prescribed heroin for opioid-dependent patients. Compilation over the years 2013-2020.]. 2021. Accessed February 12 2024. https:\/\/www.sst.dk\/-\/media\/Udgivelser\/2021\/Heroin\/Evaluering-af-ordningen-med-laegeordineret-heroin200121.ashx?sc_lang=da&hash=94817B3D4A998123F247F91BAFDDC120"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1159\/000313334"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/15564886.2017.1383332"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02185.x"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104025"},{"key":"e_1_3_3_53_2","unstructured":"Frey K Pestoni A H\u00e4usermann M. Situationsanalyse der heroingest\u00fctzten Behandlung (He-GeBe). 2021. https:\/\/www.bag.admin.ch\/dam\/bag\/de\/dokumente\/e-f\/evalber-ncd-sucht\/2021-situationsanalyse-hegebe-schlussbericht.pdf.download.pdf\/2021-schlussbericht-situationsanalyse-hegebe-d.pdf"},{"key":"e_1_3_3_54_2","unstructured":"Danish Health Authority. Vejledning til l\u00e6ger der behandler opioidafh\u00e6ngige patienter med substitutionsmedicin [Guidance for doctors treating opioid-dependent patients with substitution medication]. 2017. Accessed February 12 2024. https:\/\/www.sst.dk\/da\/sundhed-og-livsstil\/narkotika\/~\/media\/796D337DC66D4F72A8991141B88BD699.ashx"},{"key":"e_1_3_3_55_2","doi-asserted-by":"crossref","unstructured":"Blanken P Hendriks VM Huijsman IA van Ree JM van den Brink W. Efficacy of cocaine contingency management in heroin-assisted treatment: results of a randomized controlled trial. Drug Alcohol Depend. 2016;164:55-63. doi:https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.04.018","DOI":"10.1016\/j.drugalcdep.2016.04.018"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00785-y"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.06.009"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.03.016"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241271991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342241271991","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241271991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:50:14Z","timestamp":1777600214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342241271991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/29767342241271991"],"URL":"https:\/\/doi.org\/10.1177\/29767342241271991","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]}}}